Journals / İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2017 / Cilt: 21 - Sayı: 3

EFFECTIVENESS OF HIGH DOSE METHYL PREDNISOLON AS STANDART DOSE STEROID-RESISTANT CHRONIC IMMUNE THROMBOCYTOPENIA SPLENECTOMY PREPARING REGIME

STANDART DOZ STEROİDE DİRENÇLİ KRONİK İMMÜN TROMBOSİTOPENİDE SPLENEKTOMİYE HAZIRLAYICI REJİM OLARAK YÜKSEK DOZ METİL PREDNİZOLON’UN ETKİNLİĞİ

Pages
77–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: High dose methylprednisolone is an effective and safe treatment option for splenectomy preparation in ITP patients resistant to standard dose prednisolone treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Immune thrombocytopenia (ITP) is an acquired disease that results in reduced platelet count and shortened life span due to immun destruction.
📊
Key Findings & Data:Standard dose steroid is used in the 1st step treatment.
💡
Conclusion & Impact:Conclusion: High dose methylprednisolone is an effective and safe treatment option for splenectomy preparation in ITP patients resistant to standard dose prednisolone treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Immune thrombocytopenia (ITP) is an acquired disease that results in reduced platelet count and shortened life span due to immun destruction. Standard dose steroid is used in the 1st step treatment. There are no advantages of splenectomy with the use of many agents in this treatment-free patients. We investigated the efficacy of high dose prednisolone as a preparatory regimen in our patients who underwent splenectomy in our clinic. Material and Methods: This study evaluated the outcomes of 35 patients with chronic ITP who underwent splenectomy because of their standardized dose of steroids resistant to treatment and follow-up between 1996 and 1999. Results: Of the 35 patients, 25 were female (71.4%), 10 were male, median age was 39.91 (17-79 years), and duration of illness was 3 (1-9) years. All patients received 1 mg / kg methylprednisolone as initial therapy. Splenectomy was performed for this patient who did not respondad equately to this treatment or relapsed after the response. Platelet count ranged from 3x109 /L to 48x109 /L (mean 18.94x109 /L). High-dose methylprednisolone was used as the splenectomy preparation regimen. There was no significant side effect in the preparation process and after splenectomy and the treatment was complete response. Conclusion: High dose methylprednisolone is an effective and safe treatment option for splenectomy preparation in ITP patients resistant to standard dose prednisolone treatment.

Özet

Amaç: İmmüntrombositopeni (ITP), immün yıkım nedeniyle trombosit sayısının azalması ve yaşam süresinin kısalması sonucu gelişen edinsel bir hastalıktır. 1. Basamak tedavide standart doz steroid kullanılmaktadır. Bu tedaviye yanıtsız hastalarda birçok ajan kullanılmakla birlikte splenektomiye üstünlükleri bulunmamaktadır. Kliniğimizde splenektomi uygulanan hastalarımızda hazırlayıcı rejim olarak yüksek doz prednizolonun etkinliğini araştırdık. Gereç ve Yöntem: Bu çalışmada 1996 - 1999 yılları arasında tedavi ve takipleri merkezimizce yapılan standart doz steroide dirençli oldukları için splenektomi uygulanan kronik ITP’li35 hastanın sonuçları değerlendirilmiştir. Bulgular: 35 hastanın 25’i kadın (%71,4), 10’u erkek, ortanca yaş 39,91 (17 - 79 yıl), hastalığın süresi 3 (1-9)yıl idi. Tüm hastalar başlangıç tedavisi olarak 1 mg/kg metil prednizolon almıştı. Bu tedaviye yeterli yanıt vermeyen ya da yanıt sonrası nüks eden bu hastalara splenektomi uygulandı.Trombosit değerleri 3x109 /L ile 48x109 /L arasında değişmekteydi (ortalama 18,94 x109 /L). Splenektomiye hazırlayıcı rejim olarak yüksek doz metil prednizolon kulllanıldı. Hazırlık sürecinde ve splenektomi sonrasında hastalarda önemli bir yan etki olmadı ve tedaviye tam yanıt alındı. Sonuç: Standart doz prednizolon tedavisine dirençli ITP hastalarında splenektomiye hazırlık rejimi olarak yüksek doz metil prednizolon etkili ve güvenli bir tedavi seçeneğidir.

🔖

Cite This Article

BİLGİR, F. (2017). EFFECTIVENESS OF HIGH DOSE METHYL PREDNISOLON AS STANDART DOSE STEROID-RESISTANT CHRONIC IMMUNE THROMBOCYTOPENIA SPLENECTOMY PREPARING REGIME. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 21 - Sayı: 3, 77–82. https://ajindex.com/articles/199201

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: what’s the same, what’sdifferent? Haematologica 2011;96(12):1739-41.
  2. Neunert C, Lim W, Crowther M, Cohen A,Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190- 4207. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. 2014;43(4 Pt 2):e49-e59. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nation wide population-based study in France. Blood 2014;124(22):3308-15.
  3. Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016;23(5):479-85.
  4. Matschke J, Müller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-native adult patients with immune thrombocytopenia:EIS 2002 Study. Acta Haematol 2016;136(2):101-7.
  5. Din B, Wang X, Shi Y, Li Y. Long-term effect of high-dose dexamethasone with or without low dose dexamethasone maintenance in untreated immune thrombocytopenia. Acta Haematol 2015;133(1):124-8.
  6. Wei Y, Ji XB, Wang YW,Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 2016;127(3):296-302.
  7. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115(14):2755-62.
  8. Gudbrandsdottir S, Birgens HS, Frederiksen H,Jensen BA, Jensen MK, Kjeldsen L,et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013;121(11):1976-81.
  9. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB,et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168-86.
  10. Berchtold P, McMillion R, Therapy of ITP in adults. Blood 1989;74:2309-17.
  11. George JN. El Hareke MA, Baskob GE. Chronic ITP. N Eng J Med 1994;333:1207-11.
  12. Ben Yehuda D, Gillis S, Eldor A.Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. ActaHaematol 1994;91(1):1